<!DOCTYPE html>
<html lang="en">
<partial title="Research - Gennova Biopharmaceuticals" name="head.html"></partial>

<body>
  <partial name="header.html" />
  <section class="
        md:h-500
        h-36
        px-4
        md:px-8
        lg:px-0
        w-full
        flex
        items-center
        lg:items-start
      " style="
        background-image: url('./assets/images/research-gennova.png');
        background-size: cover;
      ">
    <div class="container max-w-wrapper mx-auto">
      <div class="lg:mt-32">
        <h1 class="
              uppercase
              tracking-heading
              text-xl
              font-semibold
              text-primary-heading
              md:mb-3.5
            ">
          research
        </h1>
        <div class="redStrip h-2 my-1 md:my-4 w-20"></div>
        <h2 class="
              font-semibold
              text-primary-heading text-xl
              lg:text-54 lg:leading-55
              tracking-tight
            ">
          Gennova Biopharmaceuticals
        </h2>
      </div>
    </div>
  </section>
  <section class="redStrip px-4 md:px-8 w-full h-20 md:h-40 mb-60 py-12">
    <div class="container max-w-wrapper mx-auto">
      <div class="
            bg-white
            rounded-xl
            shadow-2xl
            md:flex
            items-center
            justify-between
            px-8
            lg:px-32
            py-8
            lg:mx-12 lg:py-20
          ">
        <img src="./assets/images/Gennova-Logo-footer.png" class="self-start" alt="" />
        <button class="
              button
              my-5
              items-center
              lg:px-10
              px-6
              py-3
              text-white
              bg-primary
              rounded-md
            ">
          <a href="https://gennova.bio/" target="_blank"> Visit Site</a>
        </button>
      </div>
    </div>
  </section>
  <section>
    <div class="container max-w-5xl px-10 mx-auto">
      <h2 class="
            font-semibold
            text-primary-heading text-2xl
            md:text-4xl
            leading-34
            md:leading-55
          ">
        Realizing the importance and potential of biologics and new
        technology, Emcure incorporated its biotechnology arm, Gennova
        Biopharmaceuticals Ltd. India, in 2002
      </h2>
      <p class="text-primary-body mt-8 my-2">
        Gennova is dedicated to the development and production of
        bio-therapeutics to address life-threatening diseases across various
        areas. Gennova has multiple collaborations with research institutes
        and organizations across the globe which have helped build its
        expertise.
      </p>
      <p id="reveal1" class="my-5 hidden text-primary-body">
        Gennova is transforming healthcare by creating efficient and effective
        solutions for manufacturing and successfully commercializing
        bio-therapeutics across therapies. The company manufactures its
        recombinant products using microbial and mammalian-based expression
        platforms. It has developed deep expertise in perfusion-based
        continuous manufacturing technologies. Incorporating recombinant DNA
        technologies and innovative bio-manufacturing practices, Gennova has
        commercialized six biologics including one pioneering – 'first in the
        world' product.<br />
        <br />
        Gennova has also developed India’s first mRNA vaccine against the
        SARS-CoV-2 genome which is currently under Phase-1 trials. HGC019 has
        already demonstrated safety, immunogenicity, neutralization antibody
        activity in the rodent and non-human primate models.
      </p>
      <button onclick="revealText(event,'reveal1')" class="
            button
            my-10
            mr-4
            btn-90
            items-center
            lg:px-10
            px-6
            py-3
            text-white
            bg-primary-footer
            rounded-md
          ">
        Read More
      </button>
    </div>
  </section>
  <div class="
        container
        px-4
        lg:px-0 lg:mt-24
        md:my-32
        mt-5
        max-w-wrapper
        mx-auto
      ">
    <div class="grid md:grid-cols-2 grid-cols-1 gap-4 md:gap-8">
      <div class="w-full relative overflow-hidden rounded-xl bg-cover h-52"
        style="background-image: url('./assets/images/biologics/4.png')">
        <div class="
              w-full
              h-full
              absolute
              bg-gradient-to-t
              from-black
              via-transparent
              to-transparent
            ">
          <div class="w-full h-full text-white p-4 flex items-end">
            <div>
              <h3 class="text-2xl font-medium mb-2">Cardiovascular</h3>
              <ul class="list-disc grid grid-cols-2 gap-6 ml-4">
                <li>Elaxmin</li>
              </ul>
            </div>
          </div>
        </div>
      </div>
      <div class="w-full relative overflow-hidden rounded-xl bg-cover h-52"
        style="background-image: url('./assets/images/biologics/1.png')">
        <div class="
              w-full
              h-full
              absolute
              bg-gradient-to-t
              from-black
              via-transparent
              to-transparent
            ">
          <div class="w-full h-full text-white p-4 flex items-end">
            <div>
              <h3 class="text-2xl font-medium mb-2">Neurology</h3>
              <ul class="list-disc grid grid-cols-2 gap-6 ml-4">
                <li>TENECTASE</li>
              </ul>
            </div>
          </div>
        </div>
      </div>
      <div class="w-full relative overflow-hidden rounded-xl bg-cover h-52"
        style="background-image: url('./assets/images/biologics/3.png')">
        <div class="
              w-full
              h-full
              absolute
              bg-gradient-to-t
              from-black
              via-transparent
              to-transparent
            ">
          <div class="w-full h-full text-white p-4 flex items-end">
            <div>
              <h3 class="text-2xl font-medium mb-2">Nephrology</h3>
              <ul class="list-disc grid grid-cols-2 gap-6 ml-4">
                <li>Vibtor</li>
              </ul>
            </div>
          </div>
        </div>
      </div>
      <div class="w-full relative overflow-hidden rounded-xl bg-cover h-52"
        style="background-image: url('./assets/images/biologics/2.png')">
        <div class="
              w-full
              h-full
              absolute
              bg-gradient-to-t
              from-black
              via-transparent
              to-transparent
            ">
          <div class="w-full h-full text-white p-4 flex items-end">
            <div>
              <h3 class="text-2xl font-medium mb-2">Oncology</h3>
              <ul class="list-disc grid grid-cols-2 gap-1 ml-4">
                <li>Xgrast</li>
                <li>PEGEX</li>
                <li>HAMSYL</li>
                <li>Emgrast-M</li>
              </ul>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <section class="my-20">
    <div class="grid grid-cols-12">
      <div class="lg:col-span-5 col-span-12">
        <img class="w-full h-400 object-cover" src="./assets/images/research-gennova2.png" alt="" />
      </div>
      <div class="lg:col-span-6 2xl:col-span-4 col-span-12">
        <div class="px-4 md:px-8 py-10 md:py-4 lg:py-0 lg:px-24">
          <h2 class="
                font-semibold
                text-4xl
                leading-55
                text-primary-heading
                mb-10
              ">
            Vaccines Research & Development
          </h2>
          <p class="text-primary-body leading-30">
            Gennova over the past few years has been working on developing an
            mRNA platform for developing bio-therapeutics and vaccines. It
            currently has four vaccines in its pipeline including India’s
            first indigenously developed mRNA vaccine, HGC019 which is in
            Phase I clinical trials. Gennova is also leveraging this
            technology to develop vaccines for Zika, Rabies and Zoster which
            are in the pre- clinical stage.
          </p>
          <p id="reveal2" class="my-5 hidden text-primary-body">
            Establishment of such a technology platform will not only empower
            Emcure to handle unique situations such as the COVID-19 pandemic,
            but also ensure preparedness for any future medical urgencies by
            utilizing its rapid development path.
          </p>

          <button onclick="revealText(event,'reveal2')" class="
                button
                my-10
                mr-4
                btn-90
                items-center
                lg:px-10
                px-6
                py-3
                text-white
                bg-primary-footer
                rounded-md
              ">
            Read More
          </button>
        </div>
      </div>
    </div>
  </section>
  <section class="redStrip px-4 md:px-8 w-full lg:h-80 py-12">
    <div class="max-w-wrapper mx-auto">
      <div class="md:flex text-white">
        <div class="md:w-2/5">
          <div class="md:flex">
            <img class="self-center mx-4" src="./assets/images/mrna.png" alt="" />
            <p class="
                  font-semibold
                  text-2xl
                  leading-25
                  lg:text-4xl lg:leading-55
                  tracking-sectionH
                ">
              What are mRNA vaccines?
            </p>
          </div>
        </div>
        <div class="md:w-3/5 my-14 md:my-0 md:mb-10 md:px-10">
          <p class="leading-30">
            In a standard viral vaccine, either inactivated (or attenuated)
            virus or viral proteins known to cause the infection are used for
            immunization. However, an mRNA vaccine carries the molecular
            instructions to make the protein in the body through a synthetic
            RNA of the virus. The host body uses this to produce the viral
            protein that is recognized by the immune system, thereby making
            the body ready to fight against the disease.
          </p>
        </div>
      </div>
    </div>
  </section>
  <section class="-mt-20 lg:-mt-24 px-2 lg:px-0">
    <div class="container max-w-wrapper mx-auto mb-10 lg:mb-40">
      <div class="lg:mx-24">
        <div class="
              bg-white
              rounded-xl
              border border-gray-100
              transition-all
              duration-100
              shadow-transparent shadow-2xl
              overflow-hidden
              px-8
              lg:px-14
              py-8
              my-4 my-10
            ">
          <div class="dropdown opened">
            <h2 class="h2 lg:text-3xl mb-7">
              What are the advantages of mRNA vaccines?
            </h2>
            <svg xmlns="http://www.w3.org/2000/svg" class="h-6 w-6" fill="none" viewBox="0 0 24 24"
              stroke="currentColor">
              <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7" />
            </svg>
          </div>
          <div class="transition-all duration-100 ease-linear">
            <img class="mb-5" src="./assets/images/ourbusiness-vaccine-1.jpg" alt="" />
            <ul class="">
              <li class="red-dot baseline mb-4 text-primary-body">
                Novel vaccine development can take anywhere between 10 – 15
                years. Considering the immediate need for a vaccine against
                COVID 19, the developmental time for the vaccine is critical.
                mRNA vaccines are thus, the ideal choice given their rapid
                developmental timeline
              </li>
              <li class="red-dot baseline mb-4 text-primary-body">
                mRNA vaccines are considered safe as the mRNA is
                non-infectious, non-integrating in nature and degraded by
                normal cellular mechanisms. They are highly efficacious
                because of their inherent capability of being translatable
                into the protein structure inside the cell cytoplasm
              </li>
              <li class="red-dot baseline mb-4 text-primary-body">
                Additionally, mRNA vaccines are fully synthetic and do not
                require a host for growth, example eggs or bacteria.
                Therefore, they have a shorter manufacturing lead time
              </li>
            </ul>
          </div>
        </div>
        <div class="my-2 h-px bg-primary-light bg-opacity-30"></div>

        <div class="
              bg-white
              rounded-xl
              border border-gray-100
              transition-all
              duration-100
              shadow-transparent
              h-28
              overflow-hidden
              px-8
              lg:px-14
              py-8
              my-4
            ">
          <div class="dropdown">
            <h2 class="h2 lg:text-3xl mb-7">
              How does the mRNA vaccine, HGCO19, work against the coronavirus?
            </h2>
            <svg xmlns="http://www.w3.org/2000/svg" class="h-6 w-6" fill="none" viewBox="0 0 24 24"
              stroke="currentColor">
              <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7" />
            </svg>
          </div>
          <div class="transition-all duration-100 ease-linear opacity-0">
            <img class="mb-5" src="./assets/images/ourbusiness-vaccine-2.jpg" alt="" />
            <ul class="">
              <li class="red-dot baseline mb-4 text-primary-body">
                The novel mRNA vaccine candidate, HGC019, has all the
                necessary information to guide the host cells to make the
                antigen – spike protein of the virus, reported to interact
                with host cells receptor, and supported by ‘lipid inorganic
                nanoparticle (LION™)’ as a delivery vehicle
              </li>
              <li class="red-dot baseline mb-4 text-primary-body">
                When the vaccine is injected into the body the synthetic mRNA
                is taken to muscle cells where it instructs the cells to make
                numerous copies of the mRNA and antigen
              </li>
              <li class="red-dot baseline mb-4 text-primary-body">
                The coronavirus also uses its RNA genome guided approach to
                multiply and express viral proteins within the human body
                cells. Hence, Gennova’s approach which is similar to this
                action, gives it an advantage over other vaccine candidates to
                present the identically folded form of spike protein of
                coronavirus as it is reported during its infection cycle
              </li>
              <li class="red-dot baseline mb-4 text-primary-body">
                Other immune cells then act on the spike proteins and in the
                process learn to identify the coronavirus and protect the body
                if the person were ever to be actually infected
              </li>
              <li class="red-dot baseline mb-4 text-primary-body">
                The mRNA is associated with the ‘lipid inorganic nanoparticle
                (LION™) and acts as mRNA vaccine delivery system’ which
                stabilizes the mRNA and acts as adjuvant till delivery into
                patients
              </li>
            </ul>
          </div>
        </div>

        <div class="my-2 h-px bg-primary-light bg-opacity-30"></div>

        <div class="
              bg-white
              rounded-xl
              border border-gray-100
              transition-all
              duration-100
              shadow-transparent
              h-28
              overflow-hidden
              px-8
              lg:px-14
              py-8
              my-4
            ">
          <div class="dropdown">
            <h2 class="h2 lg:text-3xl mb-7">
              What makes HGCO19 a unique vaccine candidate against COVID- 19?
            </h2>
            <svg xmlns="http://www.w3.org/2000/svg" class="h-6 w-6" fill="none" viewBox="0 0 24 24"
              stroke="currentColor">
              <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7" />
            </svg>
          </div>
          <div class="transition-all duration-100 ease-linear opacity-0">
            <img class="mb-5" src="./assets/images/ourbusiness-vaccine-3.jpg" alt="" />
            <ul class="">
              <li class="red-dot baseline mb-4 text-primary-body">
                HGCO19 uses the self-amplifying mRNA platform which gives it
                the advantage of a low dosing regimen
              </li>
              <li class="red-dot baseline mb-4 text-primary-body">
                HGCO19 is stable at 2-8°C
              </li>
            </ul>
            <img class="mb-5" src="./assets/images/image2.jpeg" alt="" />
          </div>
        </div>
      </div>
    </div>
  </section>
  <section class="redStrip px-4 md:px-8 w-full lg:h-80 py-12">
    <div class="max-w-wrapper mx-auto">
      <div class="md:flex text-white">
        <div class="md:w-2/5">
          <div class="md:flex">
            <img class="self-center mx-4" src="./assets/images/science-research.png" alt="" />
            <p class="
                  font-semibold
                  text-2xl
                  leading-25
                  lg:text-4xl lg:leading-55
                  tracking-sectionH
                ">
              Biologics Research & Development
            </p>
          </div>
        </div>
        <div class="md:w-3/5 my-14 md:my-0 md:mb-10 md:px-10">
          <p class="leading-30">
            Emcure Pharmaceuticals is committed to delivering high- quality
            biologics that are affordable. It is also in the process of
            developing new delivery systems which allow ease of use. Gennova
            has worked on a platform strategy with a focus on developing
            platforms and then using these to launch multiple products. It
            currently has two established biologics platforms – Mammalian and
            Microbial.
          </p>
        </div>
      </div>
    </div>
  </section>
  <section class="-mt-20 lg:-mt-20 px-2 lg:px-0">
    <div class="container max-w-wrapper mx-auto mb-10 lg:mb-40">
      <div class="lg:mx-24">
        <div class="
              bg-white
              rounded-xl
              border border-gray-100
              transition-all
              duration-100
              shadow-transparent shadow-2xl
              overflow-hidden
              px-8
              lg:px-14
              py-8
              my-4 my-10
            ">
          <div class="dropdown opened">
            <h2 class="h2 lg:text-3xl mb-7">Mammalian</h2>
            <svg xmlns="http://www.w3.org/2000/svg" class="h-6 w-6" fill="none" viewBox="0 0 24 24"
              stroke="currentColor">
              <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7" />
            </svg>
          </div>
          <div class="transition-all duration-100 ease-linear">
            <p class="text-primary-body">
              Gennova has concentrated its research and development efforts to
              create specifically designed mammalian production cell lines
              that can survive more than 90 days in a perfusion-based
              bioreactor system. This innovative approach has allowed Gennova
              to not only commercialize these life-saving bio-therapeutics at
              an affordable price but also achieve high-quality & uniformity
              across batches which is a key challenge in biologic production.
              Gennova is also leveraging AI tools to improve manufacturing
              processes, quality and yields of products. It also intends to
              employ Machine Learning Algorithms to develop next-gen, data
              driven automated bio-manufacturing processes to minimize
              manufacturing deviations and meet regulatory compliance and
              improve cost efficiencies.
            </p>
            <p class="text-primary-body my-4">
              Continuous Bio-manufacturing:
            </p>
            <img src="./assets/images/tableimage.png" alt="" />
            <table class="w-full border border-gray-100">
              <thead class="bg-primary text-white">
                <tr>
                  <td class="
                        border border-gray-100
                        block
                        md:table-cell
                        px-14
                        py-4
                        font-semibold
                        text-3xl
                        leading-34
                      ">
                    Product
                  </td>
                  <td class="
                        border border-gray-100
                        block
                        md:table-cell
                        px-14
                        py-4
                        font-semibold
                        text-3xl
                        leading-34
                      ">
                    Benefit
                  </td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td class="
                        border border-gray-100
                        block
                        text-primary-body
                        md:table-cell
                        px-10
                      ">
                    Tenecteplase for AMI
                  </td>
                  <td class="border border-gray-100 block md:table-cell px-10">
                    <ul class="text-primary-body list-disc">
                      <li class="px-4 py-2">
                        Tenecteplase, a third gen- thrombolytic, is a fibrin
                        specific tissue plasminogen activator which is a much
                        faster clot buster than the previous gen- alteplase
                      </li>
                      <li class="px-4 py-2">
                        It has greater fibrin specificity (by 14 folds)
                        allowing for faster and more complete clot lysis with
                        decreased bleeding complications
                      </li>
                      <li class="px-4 py-2">
                        It has a longer half- life which permits a single
                        bolus dose
                      </li>
                      <li class="px-4 py-2">
                        Tenecteplase, a third gen- thrombolytic, is a fibrin
                        specific tissue plasminogen activator which is a much
                        faster clot buster than the previous gen- alteplase
                      </li>
                      <li class="px-4 py-2">
                        It has an increased resistance to degradation by
                        plasminogen activator inhibitor- 1
                      </li>
                      <li class="px-4 py-2">
                        It has an improved production yield of Elaxim by more
                        than 100% within the same facility
                      </li>
                    </ul>
                  </td>
                </tr>
                <tr>
                  <td class="
                        border border-gray-100
                        block
                        text-primary-body
                        md:table-cell
                        px-10
                      ">
                    Tenecteplase for AIS
                  </td>
                  <td class="border border-gray-100 block md:table-cell px-10">
                    <ul class="text-primary-body list-disc">
                      <li class="px-4 py-2">
                        Gennova holds a global patent for Tenectase for this
                        indication
                      </li>
                      <li class="px-4 py-2">
                        Gennova introduced the first ever third-generation
                        thrombolytic, tenecteplase approved for the indication
                        of Acute Ischemic Stroke (AIS)
                      </li>
                      <li class="px-4 py-2">
                        This offers much better efficacy than current first
                        line treatments
                      </li>
                    </ul>
                  </td>
                </tr>
              </tbody>
            </table>
          </div>
        </div>
        <div class="
              bg-white
              rounded-xl
              border border-gray-100
              transition-all
              duration-100
              shadow-transparent
              h-28
              overflow-hidden
              px-8
              lg:px-14
              py-8
              my-4
            ">
          <div class="dropdown">
            <h2 class="h2 lg:text-3xl mb-7">Microbial</h2>
            <svg xmlns="http://www.w3.org/2000/svg" class="h-6 w-6" fill="none" viewBox="0 0 24 24"
              stroke="currentColor">
              <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19 9l-7 7-7-7" />
            </svg>
          </div>
          <div class="transition-all duration-100 ease-linear opacity-0">
            <div>
              <p class="text-primary-body my-4 md:my-2 leading-30">
                Gennova's innovation around high cell density fermentation,
                genetic manipulations for its microbial products and a
                cost-effective pegylation technology puts it in a unique
                position to address the problems of quality, affordability and
                availability of the portfolio of products.<br />
                The key innovations include:
              </p>
              <table class="w-full border border-gray-100">
                <thead class="bg-primary text-white">
                  <tr>
                    <td class="
                          border border-gray-100
                          block
                          md:table-cell
                          px-14
                          py-4
                          font-semibold
                          text-3xl
                          leading-34
                        ">
                      Product
                    </td>
                    <td class="
                          border border-gray-100
                          block
                          md:table-cell
                          px-14
                          py-4
                          font-semibold
                          text-3xl
                          leading-34
                        ">
                      Benefit
                    </td>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td class="
                          border border-gray-100
                          block
                          text-primary-body
                          md:table-cell
                          px-10
                        ">
                      Pegaspargase: Hamsyl Commercial
                    </td>
                    <td class="border border-gray-100 block md:table-cell px-10">
                      <ul class="text-primary-body list-disc">
                        <li class="px-4 py-2">
                          First Indian company to launch pegaspargase
                        </li>
                        <li class="px-4 py-2">
                          pegylated form of 'native asparaginase' and it deals
                          with the hypersensitivity issue of 'native
                          asparaginase' hence, is used as the first-line
                          treatment for ALL
                        </li>
                        <li class="px-4 py-2">
                          Because of its longer half, requirement of fewer
                          dose and sustained therapeutic activity through the
                          course, it is preferred over asparaginase
                        </li>
                      </ul>
                    </td>
                  </tr>
                  <tr>
                    <td class="
                          border border-gray-100
                          block
                          text-primary-body
                          md:table-cell
                          px-10
                        ">
                      Recombinant Asparaginase: Pipeline
                    </td>
                    <td class="border border-gray-100 block md:table-cell px-10">
                      <ul class="text-primary-body list-disc">
                        <li class="px-4 py-2">
                          Gennova has developed Recombinant Asparaginase as a
                          novel way of ensuring quality to cater to stringent
                          regulatory rules and ensuring affordability
                        </li>
                        <li class="px-4 py-2">
                          It has also developed Recombinant Pegaspargase which
                          assures quality, stable storage and is more safe,
                          effective and economical for treatment of ALL
                        </li>
                      </ul>
                    </td>
                  </tr>
                </tbody>
              </table>
            </div>
          </div>
        </div>
      </div>
    </div>
  </section>
  <!-- Research Footer -->

  <partial name="redstrip-section.html" title="Know More" css-prev="myswiper-button-prev"
    css-next="myswiper-button-next" />
  <section class="-mt-20">
    <div class="w-full h-350 overflow-hidden swiper-container mySwiper2">
      <div class="flex swiper-wrapper">
        <partial name="slider/slide-square.html" image="./assets/images/research/1.png" title="APIs" />
        <partial name="slider/slide-square.html" image="./assets/images/research/2.png" title="Formulations" />
        <partial name="slider/slide-square.html" image="./assets/images/research/3.png" title="Overview" />
        <partial name="slider/slide-square.html" image="./assets/images/research/5.png" title="Biologics" />
        <partial name="slider/slide-square.html" image="./assets/images/research/4.png" title="R&D Locations" />
      </div>
    </div>
  </section>
  <div class="md:h-20"></div>
  <partial name="redstrip-section.html" title="Quick Explore" css-prev="myswiper2-button-prev"
    css-next="myswiper2-button-next" />
  <section class="-mt-20">
    <div class="w-full h-350 overflow-hidden swiper-container mySwiper2">
      <div class="flex swiper-wrapper">
        <partial name="slider/slide-square.html" image="./assets/images/aboutus/4.png" title="About us" />
        <partial name="slider/slide-square.html" image="./assets/images/aboutus/1.png" title="Research" />
        <partial name="slider/slide-square.html" image="./assets/images/aboutus/2.png" title="Careers" />

      </div>
    </div>
  </section>
  <div class="md:h-20"></div>

  <partial name="footer.html" />





  <script src="https://unpkg.com/swiper/swiper-bundle.min.js"></script>
  <script src="https://unpkg.com/scrollreveal"></script>
  <script src="./script.js"></script>
  <script>
    const toggleMenu = () => {
      document.getElementById("menu").classList.toggle("hidden");
    };
    allMenuItems = document.querySelectorAll("#menu li");
    allMenuItems.forEach((item) => {
      if (item.firstElementChild) {
        item.addEventListener("click", () => {
          item.firstElementChild.classList.toggle("hidden");
        });
      }
    });
    window.onload = (event) => {
      var swipera = new Swiper(".mySwiper", {
        spaceBetween: 30,
        slidesPerView: "auto",
        autoplay: {
          delay: 3000,
        },
        loop: true,
        navigation: {
          nextEl: ".myswiper-button-next",
          prevEl: ".myswiper-button-prev",
        },
      });
      var swiperb = new Swiper(".mySwiper2", {
        spaceBetween: 30,
        slidesPerView: "auto",
        autoplay: {
          delay: 3000,
        },
        loop: true,
        navigation: {
          nextEl: ".myswiper2-button-next",
          prevEl: ".myswiper2-button-prev",
        },
      });
      new Swiper(".swiper-3", {
        spaceBetween: 30,
        slidesPerView: "auto",
        autoplay: {
          delay: 3000,
        },
        loop: true,
      });
    };

    const revealText = (event, id) => {
      if (document.getElementById(id).classList.contains("hidden")) {
        event.target.innerHTML = "Read Less";
      } else {
        event.target.innerHTML = "Read More";
      }
      event.target.classList.toggle("opened");
      document.getElementById(id).classList.toggle("hidden");
    };
    const expandables = document.querySelectorAll(".dropdown");
    expandables.forEach((expandable) => {
      expandable.parentElement.style.minHeight =
        expandable.offsetHeight + 32 + "px";
      expandable.addEventListener("click", () => {
        expandable.parentElement.classList.toggle("h-28");

        expandable.parentElement.classList.toggle("shadow-2xl");
        expandable.parentElement.classList.toggle("my-10");
        expandable.nextElementSibling.classList.toggle("opacity-0");

        expandable.classList.toggle("opened");
      });
    });
  </script>
</body>

</html>